# OnCo record endometrial-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/endometrial-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "endometrial-cancer-signalling" ;
  schema:name "Endometrial cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05213"@en, "Endometrial cancer"@en ;
  schema:description "KEGG's endometrial cancer map shows oestrogen-related type I tumours with PTEN loss, KRAS and beta-catenin mutations and faulty mismatch repair, and type II tumours with TP53 mutation and HER2 amplification. Immunotherapy for mismatch-repair-deficient tumours and HER2-directed therapy follow directly from this split."@en ;
  schema:url <https://onco.cc/pathways/endometrial-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05213>, <https://doi.org/10.1016/S0140-6736(22)00323-3> ;
  onco:related <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:cancers <https://onco.cc/cancers/endometrial/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/everolimus/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/er-signaling/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-crosbie-lancet/> .